Stem Cell Therapeutics Corp. Announces Completion of Enrollment in Key Modified REGENESIS Phase IIb Stroke Trial
CALGARY, ALBERTA–(Marketwire – 03/31/10) – Stem Cell Therapeutics Corp. (”SCT” or the “Company”) (TSX-V: SSS – News ) announced today that it closed patient enrollment of the modified Phase IIb stroke trial on March 31st, 2010 and will analyze the data as they become available. Using a modified statistical approach the Company will analyze its trial data using the 96 patients that were enrolled …

